Xenon Pharmaceuticals Inc - Asset Resilience Ratio

Latest as of December 2025: 35.63%

Xenon Pharmaceuticals Inc (XENE) has an Asset Resilience Ratio of 35.63% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check XENE capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$349.72 Million

Cash + Short-term Investments

Total Assets

$981.67 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2025)

This chart shows how Xenon Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See Xenon Pharmaceuticals Inc balance sheet quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Xenon Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Xenon Pharmaceuticals Inc (XENE) market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$349.72 Million	35.63%
Total Liquid Assets	$349.72 Million	35.63%

Asset Resilience Insights

Very High Liquidity: Xenon Pharmaceuticals Inc maintains exceptional liquid asset reserves at 35.63% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Xenon Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio

Compare Xenon Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Argen-X F:1AE	Biotechnology	10.93%
CSL Ltd AU:CSL	Biotechnology	0.41%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
HLB Co. Ltd KQ:028300	Biotechnology	0.72%
SOLENO THERAPEUT. DL-001 F:6XC	Biotechnology	41.74%
MBX Biosciences, Inc. Common Stock NASDAQ:MBX	Biotechnology	87.20%
Tourmaline Bio Inc. NASDAQ:TRML	Biotechnology	77.17%
PharmaResources (Shanghai) Co. Ltd. A SHE:301230	Biotechnology	16.35%

Annual Asset Resilience Ratio for Xenon Pharmaceuticals Inc (2013–2025)

The table below shows the annual Asset Resilience Ratio data for Xenon Pharmaceuticals Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	35.63%	$349.72 Million	$981.67 Million	-25.04pp
2024-12-31	60.67%	$484.19 Million	$798.14 Million	+9.94pp
2023-12-31	50.73%	$489.44 Million	$964.80 Million	-20.19pp
2022-12-31	70.92%	$534.85 Million	$754.15 Million	+5.17pp
2021-12-31	65.75%	$376.09 Million	$572.01 Million	-4.02pp
2020-12-31	69.77%	$131.99 Million	$189.19 Million	-9.18pp
2019-12-31	78.95%	$116.60 Million	$147.70 Million	+36.84pp
2018-12-31	42.11%	$51.55 Million	$122.43 Million	-8.15pp
2017-12-31	50.26%	$23.18 Million	$46.12 Million	-19.46pp
2016-12-31	69.72%	$47.05 Million	$67.49 Million	--
2015-12-31	0.00%	$0.00	$63.95 Million	--
2014-12-31	13.74%	$12.02 Million	$87.42 Million	-7.04pp
2013-12-31	20.79%	$11.33 Million	$54.49 Million	--

pp = percentage points

About Xenon Pharmaceuticals Inc

NASDAQ:XENE USA Biotechnology

Market Cap

$4.02 Billion

Market Cap Rank

#4795 Global

#1590 in USA

Share Price

$51.99

Change (1 day)

-0.78%

52-Week Range

$30.30 - $62.76

All Time High

$62.76